66 ISP domain
Ligands and drugs
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.
The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.
| Superclass | Proteins | Expected | 0.25×observed / expected4× | Ratio | Significance |
|---|---|---|---|---|---|
| Homogeneous non-metal compounds | 5 | 5.3 | 0.94× | q = 1.00 | |
| Homogeneous metal compounds | 5 | 12.1 | 0.41× | q = 9.3e-3 | |
| Nucleosides, nucleotides, and analogues | 0 | 6.8 | 0 | q = 1.3e-3 | |
| Lipids and lipid-like molecules | 11 | 2.7 | 4.01× | not tested | |
| Mixed metal/non-metal compounds | 1 | 0.5 | 1.93× | not tested | |
| Organoheterocyclic compounds | 6 | 3.8 | 1.58× | not tested | |
| Benzenoids | 1 | 1.8 | 0.56× | not tested | |
| Organic acids and derivatives | 2 | 3.8 | 0.52× | not tested | |
| Organic oxygen compounds | 1 | 4.9 | 0.20× | not tested |
Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB04327 | PEE | Phosphatidylethanolamine | 21 |
| DB03317 | HEC | Ferroheme C | 8 |
| DB01728 | PEF | 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine | 3 |
| DB09270 | U10 | Ubidecarenone | 3 |
| DB01117 | AOQ | Atovaquone | 2 |
| DB02777 | PLC | Diundecyl Phosphatidyl Choline | 2 |
| DB02806 | MXE | 2-Methoxyethanol | 2 |
| DB03350 | NCO | Cobalt hexammine ion | 2 |
| DB03429 | CDL | Tetrastearoyl cardiolipin | 2 |
| DB00145 | GLY | Glycine | 1 |
| DB00172 | PRO | Proline | 1 |
| DB02686 | UMQ | Undecyl-Beta-D-Maltopyranoside | 1 |
| DB04141 | — | 2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol | 1 |
| DB04799 | — | 6-Hydroxy-5-undecyl-4,7-benzothiazoledione | 1 |
| DB07401 | — | Azoxystrobin | 1 |
| DB07636 | — | 5-Heptyl-6-hydroxy-1,3-benzothiazole-4,7-dione | 1 |
| DB07640 | DCQ | 2-decyl-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione | 1 |
| DB07763 | — | (5S)-3-ANILINO-5-(2,4-DIFLUOROPHENYL)-5-METHYL-1,3-OXAZOLIDINE-2,4-DIONE | 1 |
| DB07778 | — | (S)-famoxadone | 1 |
| DB08330 | — | METHYL (2Z)-3-METHOXY-2-{2-[(E)-2-PHENYLVINYL]PHENYL}ACRYLATE | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| FES | FE2/S2 (INORGANIC) CLUSTER | 205 |
| CL | CHLORIDE ION | 23 |
| SMA | STIGMATELLIN A | 12 |
| HEC | HEME C | 9 |
| UNL | Unknown ligand | 7 |
| 3H1 | 3-chloro-4,6-dihydroxy-2-methyl-5-{(2E,4E)-3-methyl-5-[(1R,2R,6R)-1,2,6-trimethyl-3-oxocyclohexyl]penta-2,4-dien-1-yl}benzaldehyde | 2 |
| CAmetal | CALCIUM ION | 2 |
| I7Y | (2R)-2-(methoxymethyl)-4-{[(25R)-spirost-5-en-3beta-yl]oxy}butyl 4-O-alpha-D-glucopyranosyl-beta-D-glucopyranoside | 2 |
| ICX | methyl N-[(5Z)-6-({[4-(4-iodobenzyl)phenyl]carbonyl}amino)hex-5-enoyl]glycinate | 2 |
| JHB | 7-chloranyl-3-methyl-2-[4-[[4-(trifluoromethyloxy)phenyl]methyl]phenyl]-1~{H}-quinolin-4-one | 2 |
| MGmetal | MAGNESIUM ION | 2 |
| MXE | 2-METHOXYETHANOL | 2 |
| NAmetal | SODIUM ION | 2 |
| PG0 | 2-(2-METHOXYETHOXY)ETHANOL | 2 |
| PRmetal | PRASEODYMIUM ION | 2 |
| U10 | UBIQUINONE-10 | 2 |
| GLY | GLYCINE | 1 |
| NCO | COBALT HEXAMMINE(III) | 1 |
| NImetal | NICKEL (II) ION | 1 |
| NM2 | 3-CARBOXY-N,N,N-TRIMETHYLPROPAN-1-AMINIUM | 1 |